BPC-157 vs GHK-Cu: evidence, status and structure
A side-by-side look at BPC-157 and GHK-Cu, using the data on each VALREXA profile. Neither comparison is a recommendation.
Key differences
- GHK-Cu has stronger human evidence (Early human) than BPC-157 (Preclinical).
- Their U.S. status differs: BPC-157 falls under Compounding allowed (Not FDA-approved); GHK-Cu falls under Cosmetic use only (Cosmetic use; not an approved drug).
- BPC-157 is about 3.5× heavier than GHK-Cu (~1,419.5 vs ~403.9 Da).
| BPC-157 | GHK-Cu | |
| Research class | Repair & Tissue Biology | Repair & Tissue Biology |
| Human evidence | Preclinical | Early human |
| U.S. status | Not FDA-approved | Cosmetic use; not an approved drug |
| 2026 compounding decision | Allowed for 503A pharmacies under FDA enforcement discretion (Oct 2026) | — |
| Amino acids | 15 | 3 |
| Molecular weight | ~1,419.5 Da | ~403.9 Da |
| Formula | C₆₂H₉₈N₁₆O₂₂ | Varies by form |
| Sequence | GEPPPGKPADDAGLV | GHK |
| Research period | 1990s | 1973 |
| Safety summary | Not FDA-approved for human therapeutic use; long-term safety is unknown. | Not an FDA-approved systemic peptide therapy. |
How they differ
GHK-Cu is a tiny natural tripeptide (glycine-histidine-lysine) that binds copper and is found in human blood plasma. It is used mainly in cosmetic skin products. BPC-157 is a much larger, synthetic 15-amino-acid peptide studied mostly in rodent injury models. GHK-Cu has some early human data from topical use; BPC-157 is graded Preclinical.
What each one is
BPC-157: Synthetic pentadecapeptide investigated for gastrointestinal and tissue biology. Molecular weight, sequence, research history, human evidence and regulatory status.
GHK-Cu: Copper-binding tripeptide complex studied in skin biology and wound-related models. Molecular weight, sequence, research history, human evidence and regulatory status.
Educational reference only. Nothing here is medical advice, a treatment recommendation, or dosing or sourcing guidance. Report an error.